In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

AEterna Zentaris Inc.. Trade Record

NASDAQ:AEZS AEterna Zentaris Inc. stock gains 22.53% Exit Nov 23, 2018 a Trade Record by priceseries

Trade Chart
Trade Chart AEZS Nov 8, 2018, priceSeries
About AEterna Zentaris Inc.

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. The company's product pipeline includes Zoptrex, which is in Phase III clinical study zoptarelin doxorubicin in endometrial cancer (ZoptEC) of the compound in women with advanced, recurrent, or metastatic endometrial cancer, as well as completed Phase II clinical trial for the treatment of ovarian and prostate cancer; and MACRILEN, which is in Phase III trial for use in the diagnosis of adult growth hormone deficiency. It is also developing two oncology compounds, including an Erk inhibitor and luteinizing hormone-releasing hormone-disorazol Z product candidates, which are in pre-clinical development; and AEZS-120 for the treatment of prostate cancer. Aeterna Zentaris Inc. was founded in 1991 and is headquartered in Summerville, South Carolina.

Trade Information
Trade Type
LONG
ReliabilityScore™
92.86
Entry Date
Nov 8, 2018
Entry Price
2.13
Sell Date
Nov 23, 2018
Sell Price
2.61
Net Gain
22.53%
Hold Time
10 Trading Days